Nyrada Inc - Annual Report 2021

NYRADA INC (ASX:NYR) 48 5. Other income 2021 2020 $ $ Interest received 3,989 - Grant income 50,000 50,000 Other income 53,989 50,000 6. R&D grant revenue 2021 2020 $ $ R&D grant revenue 2,286,022 1,075,414 R&D grant revenue recorded in 2021 relates to the FY2020 refund received of $976,372 and the accrued FY2021 refund of $1,309,650 (2020: $1,075,414 recognised relating to FY2019 refund). 7. Trade, other receivables and prepayments 2021 2020 $ $ Current assets R&D Tax Incentive Receivable 1,309,650 1,075,414 Prepayments 1,688 3,431 Other receivables 49,483 - 1,360,821 1,078,845 8. Trade and other payables 2021 2020 $ $ Current liabilities Trade payables 87,195 209,639 Amount owing to related party - Noxopharm Limited - 342,322 Accrued expenses 433,428 138,534 Other payables 67,406 6,388 588,029 696,883 The $342,322 Noxopharm Loan was unsecured and no interest was payable. The loan was settled in full post the March 2021 Placement.